Liver disease blood test study
Part of Cancer, Digestive system clinical trials.
This study uses a simple blood test to look for tiny particles from liver cells. It includes healthy volunteers, people with type 2 diabetes and liver scarring, and people with different stages of liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must either be healthy (no known liver disease), have type 2 diabetes with moderate to severe liver scarring, or have a diagnosis of cirrhosis (any stage).
- You cannot have an active cancer or an infection in the last 2 weeks.
- You cannot have had a blood transfusion in the last month.
- You cannot be pregnant or breastfeeding.
- You cannot be currently in another treatment trial or have been in one in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new, non-invasive way to measure liver stiffness using a device called FibroScan. It aims to make liver checkups easier and more comfortable for people with liver disease.
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
This study is testing a new way to use a FibroScan (a non-invasive liver scanner) with a single probe to measure liver health in people with chronic liver disease. If you have a long-term liver condition, this trial may help improve how liver exams are done.
This study looks at people with heavy alcohol use who may have alcohol-related liver damage. It aims to better understand liver disease risk and how it changes over time, using blood tests, some scans, and possibly stored tissue.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.